553
Participants
Start Date
November 30, 2009
Primary Completion Date
January 31, 2011
Study Completion Date
January 31, 2011
GRT3938Y
Overencapsulated tablets of GRT3983Y, 100 to 300mg daily dose, 16 weeks treatment.
Placebo
Overencapsulated tablets of placebo, 16 weeks treatment.
Site 127, Fairhope
Site 130, Homewood
Site 112, Tucson
Site 129, Escondido
Site 209, Fullerton
Site 135, Long Beach
Site 202, Northridge
Site 208, Northridge
Site 219, Northridge
Site 203, San Francisco
Site 116, Santa Ana
Site 118, Santa Ana
Site 121, Santa Ana
Site 133, Santa Ana
Site 126, Vista
Site 214, Vista
Site 201, Waterbury
Site 136, Deerfield Beach
Site 137, Deerfield Beach
Site 140, Deerfield Beach
Site 216, Deerfield Beach
Site 217, Deerfield Beach
Site 218, Deerfield Beach
Site 117, Fort Myers
Site 124, Jacksonville
Site 228, Jupiter
Site 101, Orlando
Site 226, Orlando
Site 206, Sarasota
Site 212, West Palm Beach
Site 142, Atlanta
Site 128, Chicago
Site 223, Chicago
Site 114, Leawood
Site 102, Paducah
Site 211, Baltimore
Site 108, East Bridgewater
Site 113, Las Vegas
Site 122, Princeton
Site 230, New York
Site 109, Rochester
Site 225, Asheville
Site 115, High Point
Site 227, Canton
Site 233, Cincinnati
Site 111, Toledo
Site 125, Toledo
Site 104, Philadelphia
Site 106, Philadelphia
Site 205, Philadelphia
Site 105, Austin
Site 213, Corpus Christi
Site 110, Houston
Site 123, Houston
Site 204, Houston
Site 210, Houston
Site 231, Houston
Site 131, San Antonio
Site 215, San Antonio
Site 221, San Antonio
Site 139, Provo
Lead Sponsor
Grünenthal GmbH
INDUSTRY